U.S. Patents
US 12,534,428. Issued January 27, 2026.
Title: Non-Distillative Process for Manufacturing High Purity Amphetamines.
Abstract: The invention provides a non-distillative process for manufacturing amphetamine and substituted amphetamines, comprising obtaining a highly pure phosphoramidate compound, converting the highly pure phosphoramidate compound to an amphetamine sulfate compound, concentrating the amphetamine sulfate compound in isopropanol, and then salting out the amphetamine compound directly to obtain an amphetamine salt, the amphetamine salt selected from amphetamine saccharate, amphetamine sulfate, amphetamine aspartate, alkyl-amphetamine saccharate, alkyl-amphetamine sulfate, alkyl-amphetamine aspartate, aryl-amphetamine saccharate, aryl-amphetamine sulfate, aryl- amphetamine aspartate, and mixtures thereof.
View the issued patent by clicking this link.
US 12,208,068. Issued January 28, 2025.
Title: Amphetamine Controlled Release, Prodrugs and Abuse Deterrent Dosage Forms.
Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine- class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
View the issued patent by clicking this link.
US 12,006,275. Issued June 11, 2024.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Process for Making Levoamphetamine.
Abstract: This invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.
View the issued patent by clicking this link.
US 11,717,498. Issued August 8, 2023.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms.
Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine- class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regiose- lective cuprate addition reaction with aziridine phospho- ramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
View the issued patent by clicking this link.
US 11,123,310. Issued September 21, 2021.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Amphetamine Controlled Release, Prodrug, and Abuse-Deterrent Dosage Forms.
Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
View the issued patent by clicking this link.
US 10,087,202. Issued October 2, 2018.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Chiral Aziridine Phosphoramidate Compounds.
Abstract: The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.
View the issued patent by clicking this link.
US 9,657,041. Issued May 23, 2017.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Novel Chiral Aryl or Aryl-Alkyl Phosphoramidate Dexamphetamine Precursors Having A Regioisomeric Purity >99%
Abstract: The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.
View the issued patent by clicking this link.
US 9,321,794. Issued April 26, 2016.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Synthesis of Racemic Amphetamine Derivatives by Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds
Abstract: The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.
View the issued patent by clicking this link.
US 9,278,904. Issued Mar. 8, 2016.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds
Abstract: The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.
View the issued patent by clicking this link.
Overseas Patents
European Patent EP 3478363. Issued November 14, 2024.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Process to Obtain Racemic Amphetamine with Low Amount of Impurity
Abstract: The invention relates to pharmaceutical compounds, more particularly to the formulation and use thereof of compositions resulting from the synthesis of racemic amphetamine by regioselective cuprate addition reaction with aziridine phosphoramidate compounds, including, but not limited to traditional immediate, sustained and controlled release, as well as abuse deterrent and prodrug compositions.
View the issued patent by clicking this link.
Israeli Patent 288,554. Issued February 1, 2024.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Amphetamine Controlled Release, Prodrug, and Abuse-Deterrent Dosage Forms.
Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine- class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regiose- lective cuprate addition reaction with aziridine phospho- ramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
View the issued patent by clicking this link.
UK Patent 2,616,171. Issued January 10, 2024.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Process for Making Levoamphetamine.
Abstract: This invention is related to processes for synthesis of levoamphetamine derivatives by a modification of the Barbier Cuprate reaction and novel intermediates thereby, and processes for using the same.
View the issued patent by clicking this link.
UK Patent 2,595,995. Issued September 13, 2023.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Process for Making Levoamphetamine.
Abstract: This invention is related to processes for synthesis of
levoamphetamine derivatives and novel intermediates
thereby, and processes for using the same.
View the issued patent by clicking this link.
Israeli Patent 261,366. Issued June 2, 2022.
Exclusively licensed to Pharmapotheca A from Chemapotheca.
Title: Amphetamine Controlled Release, Prodrug, and Abuse-Deterrent Dosage Forms.
Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
View the issued patent by clicking this link.
